2nd Aug 2007 17:08
Notification of major interests in shares
2 August 2007
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:
Shire plc
2. Reason for the notification State Yes/No An acquisition or disposal of voting rights Yes An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached An event changing the breakdown of voting rights Other (please specify): Revised due to DTR rules - see Section 13
3. Full name of person(s) subject to the notification obligation: Fidelity
International Limited (FIL) 4. Full name of shareholder(s) (if different from 3.): See attached schedule
5. Date of the transaction (and date on which the threshold is 26th July crossed
2007 or reached if different): 6. Date on which issuer notified: 1 August 2007t 7. Threshold(s) that is/are crossed or reached: 5% 8. Notified details:
A: Voting rights attached to shares
Class/type of Situation previous to Resulting situation after the triggering shares the Triggering transaction if possible transaction using the ISIN CODE Number Number Number Number of voting % of voting of of of rights rights Shares Voting shares Rights Direct Direct Indirect Direct Indirect GB00B0KQX869 27,815,019 27,815,019 27,763,419 4.99%
B: Financial Instruments
Resulting situation after the triggering transaction
Type of Expiration Exercise/ Number of voting % of financial date Conversion rights that may be voting instrument Period/ Date acquired if the rights instrument is exercised/converted Total (A+B) Number of voting rights % of voting rights 27,763,419 4.99%
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:
See attached schedule Proxy Voting:10. Name of the proxy holder: Fidelity International Limited (FIL) 11. Number of voting rights proxy holder will cease to hold: 51,600 12. Date on which proxy holder will cease to hold voting 26th July 2007 rights: 13. Additional information: None 14. Contact name: Sophie Hughes 15. Contact: [email protected]
(Contact at Shire plc: Vivienne Hemming, Deputy Company Secretary, 01256 894276)
Schedule:
Shares Held Nominee Management Company
358,657 Bank of New York Brussels FPM
642,200 Bank o f New York Europe LDN FII
327,057 Bermuda Trust Far East HK FIMHK
82,500 BNP Paribas, Paris ‚© FIL
12,316,709 Brown Bros Harrimn Ltd LUX FIL
79,200 Brown Brothers Harriman and Co FIL
33,100 Chase Manhttn Bk AG Frnkfrt (S FPM
23,000 HSBC Trinkaux Und Burkh AG FIL
677,781 JP Morgan, Bournemouth FII
2,688,901 JP Morgan, Bournemouth FIL
8,158,259 JP Morgan Bournemouth FISL
747,828 JP Morgan Bournemouth FPM
107,300 Master Trust Bank of Japan FIJ
60,800 Nomura Trust and Banking FIJ
24,500 Norddeutsche Landersbank FIL
83,400 Northern Trust Co FIL
239,800 Northern Trust London FIL
906,997 Northern Trust London FPM
62,800 State Str Bk and Tr Co Lndn (S FIL
44,730 State Str Bk and Tr Co Lndn (S FPM
118,100 State Street Hong Kong FIA(K) L
Fidelity International Limited (FIL) is the parent holding company for various direct and indirect subsidiaries, including Fidelity Fund Management Limited (FFML), Fidelity Fund Management Limited (FFML), Fidelity Investment Services Ltd (FISL), Fidelity Gestion (FIGEST), Fidelity Investments Advisory (Korea) Limited (FIAKL), Fidelity Investments Management (Hong Kong) Limited (FIMHK), Fidelity Pension Management (FPM), Fidelity Investments Japan (FLJ) and Fidelity Investments International (FII), investment managers for various non-US investment companies and institutional clients.
For further information please contact:
Investor Relations Clĩa Rosenfeld (Rest of the World) +44 1256 894 160 Eric Rojas (North America) +1 484 595 8252 Notes to editorsSHIRE PLC
Shire's strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.
Shire's focused strategy is to develop and market products for specialty physicians. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.
For further information on Shire, please visit the Company's website: www.shire.com.
2Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com Press Release
Registered in England 5492592Registered Office as above
SHIRE PLCRelated Shares:
Shire